Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion
Medanta expanded its bed capacity by 20% during the year
Medanta expanded its bed capacity by 20% during the year
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Global specialty pipeline accelerates growth
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Subscribe To Our Newsletter & Stay Updated